Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures

Journal of Virology

Volumn 86, Issue 12, 2012, Pages 6416-6426

  Tsibris, Athe M N ^a,b   Hu, Zixin ^b,c   Paredes, Roger ^d   Leopold, Kay E ^e   Putcharoen, Opass ^a,f,g   Schure, Allison L ^c   Mazur, Natalie ^e   Coakley, Eoin ^h,j   Su, Zhaohui ^f,k   Gulick, Roy M ⁱ   Kuritzkes, Daniel R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HARVARD UNIVERSITY   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^h MONOGRAM BIOSCIENCES   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j ABBOTT LABORATORIES   (United States)

^k Outcome Sciences   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; VICRIVIROC;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR PHYLOGENY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS MUTATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; PHYLOGENY; PIPERAZINES; PYRIMIDINES; VIRUS INTERNALIZATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864018506     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00286-12     Document Type: Article

References (64)

1. Anastassopoulou CG, et al. 2007. Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog. 3:e79. doi:10.1371/journal.ppat.0030079.
2. Anderson JA, et al. 2008. Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res. Hum. Retrovir. 24:685- 694.
3. Baldwin C, Berkhout B. 2008. Mechanistic studies of a T20-dependent human immunodeficiency virus type 1 variant. J. Virol. 82:7735-7740.
4. Baldwin CE, et al. 2004. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J. Virol. 78:12428 -12437.
5. Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP. 2009. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog. 5:e1000548.
6. Cavrois M, De Noronha C, Greene WC. 2002. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat. Biotechnol. 20:1151-1154.
7. Deeks SG, et al. 2005. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J. Infect. Dis. 192:1537-1544.
8. Delobel P, et al. 2010. Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc. AIDS 24:1382-1384.
9. Devereux HL, Emery VC, Johnson MA, Loveday C. 2001. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J. Med. Virol. 65:218 -224.
10. Domingo E, Holland JJ. 1997. RNA virus mutations and fitness for survival. Annu. Rev. Microbiol. 51:151-178.
11. Dykes C, Demeter LM. 2007. Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin. Microbiol. Rev. 20:550- 578.
12. Eigen M. 1993. Viral quasispecies. Sci. Am. 269:42- 49.
13. Fatkenheuer G, et al. 2008. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med. 359:1442-1455.
14. Gulick RM, et al. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359:1429 -1441.
15. Gulick RM, et al. 2007. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J. Infect. Dis. 196:304 -312.
16. Henrich TJ, et al. 2011. Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 antagonists. Antimicrob. Agents Chemother. 56:1931-1935.
17. Henrich TJ, et al. 2010. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate. J. Acquir. Immune Defic. Syndr. 55:420- 427.
18. Huelsenbeck JP, Ronquist F. 2001. MRBAYES: Bayesian inference of phylogenetic trees. Bioinformatics 17:754 -755.
19. Jenwitheesuk E, Samudrala R. 2005. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure. Antivir. Ther. 10:893-900.
20. Kijak GH, et al. 2002. Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J. Virol. 76:7000 -7009.
21. Kirchherr JL, et al. 2007. High throughput functional analysis of HIV-1 env genes without cloning. J. Virol. Methods 143:104 -111.
22. Kitchen CM, et al. 2009. Two-way Bayesian hierarchical phylogenetic models: an application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment. Comput. Stat. Data Anal. 53:766 -775.
23. Kitchen CM, et al. 2006. Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease. AIDS Res. Hum. Retrovir. 22:1260 -1266.
24. Kuhmann SE, et al. 2004. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 78:2790 -2807.
25. Labrosse B, et al. 2006. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J. Virol. 80:8807- 8819.
26. Larder BA, Darby G, Richman DD. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731- 1734.
27. Lassen KG, et al. 2009. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog. 5:e1000377. doi:10.1371/journal.ppat.1000377.
28. Lin NH, et al. 2010. The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. J. Virol. Methods 169:39-46.
29. Lu J, Kuritzkes DR. 2001. A novel recombinant marker virus assay for comparing the relative fitness of HIV-1 reverse transcriptase variants. J. Acquir. Immune Defic. Syndr. 27:7-13.
30. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR. 2004. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J. Virol. 78:4628-4637.
31. Marconi V, et al. 2008. Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide. J. Acquir. Immune Defic. Syndr. 48:572-576.
32. Maree AF, Keulen W, Boucher CA, De Boer RJ. 2000. Estimating relative fitness in viral competition experiments. J. Virol. 74:11067-11072.
33. Margulies M, et al. 2005. Genome sequencing in microfabricated highdensity picolitre reactors. Nature 437:376 -380.
34. Marozsan AJ, et al. 2005. Differences in the fitness of two diverse wildtype human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J. Virol. 79:7121-7134.
35. McNicholas P, et al. 2010. Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial. J. Infect. Dis. 201:1470 -1480.
36. McNicholas PM, et al. 2011. Mapping and characterization of vicriviroc resistance mutations from human immunodeficiency virus type-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1). J. Acquir. Immune Defic. Syndr. 56:222-229.
37. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB. 2009. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137:433- 444.
38. Ogert RA, et al. 2010. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology 400:145-155.
39. Ogert RA, et al. 2008. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 373:387- 399.
40. Paredes R, et al. 2009. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J. Virol. 83:2038 -2043.
41. Pastore C, et al. 2006. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-offitness mutations. J. Virol. 80:750 -758.
42. Pfaff JM, et al. 2010. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+T cells. J. Virol. 84:6505- 6514.
43. Pfizer. 2007. Maraviroc tablets NDA 22-128. Antiviral Drugs Advisory Committee (AVDAC) briefing document, p 103. www.fda.gov/OHRMS/DOCKETS/AC/07/briefing/2007-4283b1-01-Pfizer.pdf.
44. Pfizer. 2007. Maraviroc tablets NDA 22-128. Antiviral Drugs Advisory Committee (AVDAC) briefing document, p 104. www.fda.gov/OHRMS/DOCKETS/AC/07/briefing/2007-4283b1-01-Pfizer.pdf.
45. Putcharoen O, et al. 2012. HIV-1 Clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. J. Virol. 86:1119 -1128.
46. Rangel HR, et al. 2003. Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J. Virol. 77:9069 -9073.
47. Ray N, Blackburn LA, Doms RW. 2009. HR-2 mutations in HIV-1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J. Virol. 83:2989 -2995.
48. Ray N, et al. 2007. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J. Virol. 81:3240 -3250.
49. Reeves JD, et al. 2005. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J. Virol. 79:4991- 4999.
50. Richman DD, et al. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660- 1666.
51. Roche M, et al. 2011. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J. Virol. 85:4330-4342.
52. Schurmann D, et al. 2007. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 21:1293-1299.
53. Schuurman R, et al. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
54. Sharma PL, Crumpacker CS. 1997. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J. Virol. 71:8846-8851.
55. Swanstrom R, et al. 2004. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J. Infect. Dis. 190:886-893.
56. Tilton JC, et al. 2010. A maraviroc-resistant HIV-1 with narrow crossresistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol. 84:10863- 10876.
57. Troyer RM, et al. 2009. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog. 5:e1000365. doi:10.1371/journal.ppat.1000365.
58. Tsibris AM, et al. 2009. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 4:e5683. doi:10.1371/journal.pone.0005683.
59. Tsibris AM, et al. 2008. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J. Virol. 82:8210-8214.
60. Westby M, et al. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80:4909-4920.
61. Westby M, et al. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81: 2359-2371.
62. Wilke CO. 2005. Quasispecies theory in the context of population genetics. BMC Evol. Biol. 5:44.
63. Wu H, et al. 2006. Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J. Virol. 80:2380 -2389.
64. Xu L, et al. 2005. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob. Agents Chemother. 49:1113-1119.